For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenues | 0 | 131,161 | ||
| Research and development expense | 0 | 227,702 | ||
| Selling, general and administrative | 0 | 115,450 | ||
| Cost of product revenue | 0 | 5,279 | ||
| Total cost and operating expenses | 0 | 348,431 | ||
| Loss from operations | 0 | -217,270 | ||
| Other income (expense), net | 0 | 1,217 | ||
| Investment income, net | 0 | 19,701 | ||
| Gain from sale of priority review voucher | 0 | 108,000 | ||
| Total non-operating income, net | 0 | 128,918 | ||
| Loss before income taxes | 0 | 88,352 | ||
| Income tax expense | 0 | 7,144 | ||
| Net loss | -107,322,000 | -95,496 | ||
| Basic EPS | - | -1.02 | ||
| Diluted EPS | - | -1.02 | ||
| Basic Average Shares | - | 93,234,195 | ||
| Diluted Average Shares | - | 93,234,195 | ||
Day One Biopharmaceuticals, Inc. (DAWN)
Day One Biopharmaceuticals, Inc. (DAWN)